Does sotagliflozin reduce cardiovascular death and heart failure events in patients with diabetes and recent worsening heart failure?
Patients with diabetes and recent worsening heart failure
Sotagliflozin therapy, initiated before or shortly after discharge
Placebo
Total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failurecomposite
In patients with diabetes and recent worsening heart failure, sotagliflozin initiated around the time of discharge significantly reduces cardiovascular deaths and heart failure events.
In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Bhatt et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69d7f43ea2a48916bbbee7e9 — DOI: https://doi.org/10.1056/nejmoa2030183
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Deepak L. Bhatt
Michael Szarek
Philippe Gabríel Steg
New England Journal of Medicine
Harvard University
University of Michigan
Yale University
Building similarity graph...
Analyzing shared references across papers
Loading...